CVR number 34899991
Industry 72.1100 Research and experimental development on biotechnology

STRADEVO A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  15.4% 8.0% 5.3% 8.5% 18.1%  
Credit score (0-100)  15 32 44 29 7  
Credit rating  BB BB BBB BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Net sales  0 0 0 0 0  
Gross profit  79.6 11.9 154 126 44.9  
EBITDA  79.6 11.9 154 126 44.9  
EBIT  79.6 11.9 154 126 44.9  
Pre-tax profit (PTP)  84.7 32.3 134.8 95.6 55.8  
Net earnings  65.3 24.9 104.0 74.5 43.3  
Pre-tax profit without non-rec. items  84.7 32.3 135 95.6 55.8  
 
See the entire income statement

Balance sheet (kDKK) 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  771 796 900 974 1,017  
Interest-bearing liabilities  0.0 0.0 922 0.0 0.0  
Balance sheet total (assets)  831 831 1,868 1,003 1,061  
Net Debt  -421 -150 -588 -363 -176  
 
See the entire balance sheet

Volume 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  79.6 11.9 154 126 44.9  
Gross profit growth  -58.4% -85.1% 1,197.0% -18.3% -64.3%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  831 831 1,868 1,003 1,061  
Balance sheet change%  7.2% -0.1% 125.0% -46.3% 5.8%  
Added value  79.6 11.9 154.0 125.8 44.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  11.4% 3.9% 11.4% 8.8% 5.9%  
ROI %  12.4% 4.1% 11.8% 9.0% 6.1%  
ROE %  8.8% 3.2% 12.3% 8.0% 4.3%  

Solidity 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Equity ratio %  92.7% 95.8% 48.2% 97.1% 95.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -528.5% -1,259.1% -381.6% -288.6% -390.9%  
Gearing %  0.0% 0.0% 102.5% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 4.2% 6.6% 0.0%  

Liquidity 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Quick Ratio  13.8 23.9 1.9 34.5 24.3  
Current Ratio  13.8 23.9 1.9 34.5 24.3  
Cash and cash equivalent  420.5 149.5 1,510.3 363.0 175.5  

Capital use efficiency 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  770.8 795.7 899.7 974.2 1,017.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2017
2018/4
2018
2019/4
2019
2020/4
2020
2021/4
2021
2022/4
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0